|Videos|March 15, 2011

Vandetanib Advantages in Medullary Thyroid Cancer

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer


Latest CME